BIOTON S.A.

Warsaw Stock Exchange BIO.WA

BIOTON S.A. EBT Margin for the year ending December 31, 2023: 3.98%

BIOTON S.A. EBT Margin is 3.98% for the year ending December 31, 2023, a 87.52% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

BIOTON S.A. EBT Margin for the year ending December 31, 2022 was 2.12%, a -58.44% change year over year.
BIOTON S.A. EBT Margin for the year ending December 31, 2021 was 5.11%, a -72.76% change year over year.
BIOTON S.A. EBT Margin for the year ending December 31, 2020 was 18.76%, a 123.38% change year over year.
BIOTON S.A. EBT Margin for the year ending December 31, 2019 was -80.24%, a -1,375.72% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Warsaw Stock Exchange: BIO.WA

BIOTON S.A.

CEO	Mr. Jeremy Launders
IPO Date	March 31, 2005
Location	Poland
Headquarters	ul. Poznanska 12
Employees	355
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceuticals, pharmaceutical preparations, pharmaceutical substances, medications, and other pharmaceutical products in Poland, China, Thailand, Vietnam, Libya, Argentina, Ukraine, Malta, Yemen, and the Russian Federation. The company offers recombinant human and classic insulin; oral anti-diabetic medication products; dietary supplements; strips for measuring sugar in blood, as well as OTC preparation for diabetics; diabetics drugs insulin vials and cartridges, including Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. It engages in advertising, advisory, and company management activities. The company was founded in 1989 and is based in Ozarów Mazowiecki, Poland.

Key trends

Past 5 years